VECT - VectivBio Holding rallies after Piper Sandler initiates Bull rating on biopharma stock
- Piper Sandler started off coverage on clinical stage biopharma company VectivBio Holding ( NASDAQ: VECT ) with the Overweight rating.
- The investment bank has set a price target of $23 on VectivBio, which implies a potential upside of 325% from stock's last close to land near to its all-time high of $28.78.
- Stock is up 12% in early trading session on Friday.
- Seeking Alpha Quant System maintains a Buy rating on the stock while 3 Wall Street analysts give a Strong Buy and 1 triggers a Buy rating.
- Earlier (June 15): VectivBio prices $30M follow-on stock offering
For further details see:
VectivBio Holding rallies after Piper Sandler initiates Bull rating on biopharma stock